MedTrace Logo

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

NCT03357263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-11-19

No results posted yet for this study

Summary

Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

GC3114

High-dose Quadrivalent influenza vaccine

BIOLOGICAL

GCFLU Quadrivalent

Quadrivalent influenza vaccine

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Woo Joo KIm, M.D, Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-20
Primary Completion
2017-12-22
Completion
2017-12-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03357263 on ClinicalTrials.gov